SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Traders are linking Quants sharp rally to reports of a Clearing House banking initiative involving Quant, alongside its role in financial-system interoperability; the tokens limited supply is fueling a scarcity and institutional-adoption narrative. Bullish momentum dominates, but some traders warn of a sharp pullback and question how much the banking use case would directly benefit QNT.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEARs sharp rally and move to a one-year high are being linked by traders to Bitwises spot-ETF filing and planned listing, with institutional-access optimism fueling bullish discussion. Some expect the momentum to continue, while others warn of a pullback or sell-the-news reaction.

Quantinuum Inc. is a quantum computing platform that offers solutions like hardware platforms, developer tools, application libraries and solution-targeted intellectual property (“IP”). The company was founded on January 20, 2026 and is headquartered in Broomfield, CO.

Quantinuum Inc. - Ordinary Shares - Class A

Quantinuum Inc.

Quantinuums finalized $100 million CHIPS R&D award is drawing attention as traders view federal backing as validation of its quantum-computing plans. Reactions are mixed, with some welcoming the support while others question the companys valuation and volatile trading.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

CVS is rebounding after a string of losing sessions, with traders focusing on an oversold technical bounce and bullish falling-wedge and support signals. Some see the move as a recovery, while others remain cautious about whether the stock can sustain it.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is drawing attention after a sharp rebound, with traders tying the move to renewed interest in AI-agent crypto projects and Fetch/ASI product developments. The reaction is divided between hopes for a breakout and concerns that FET has lagged other AI tokens and may give back gains if Bitcoin weakens.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, and Defense. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royces ongoing share buyback and speculation about a major hyperscaler deal for data-center power systems are driving discussion. Traders see the buyback as support and anticipate further upside from AI-related power demand, while others question the unannounced deal and point to recent share-price pullbacks; the potential contract remains unconfirmed.

GEOM maps the world's oil fields, mines, rare earths, and power plants, tracks what is and isn't tokenized, and cryptographically signs every dataset it publishes. Anyone can verify what we said and when. No account, no key, no permission. Sources include the WRI Global Power Plant Database and Global Energy Monitor (CC BY 4.0), attributed in full inside the app. Most of it already exists, spread across filings and terminals no one reads. GEOM gathers it and records where each figure came from.

GEOM

Traders are focused on GEOMs proposed platform for tokenizing energy and mineral royalties, with speculation about a forthcoming demo and links to Greenland-related projects driving bullish interest. That optimism is contested by concerns about the tokens limited transparency, execution risk, and sharp pullback, with some traders viewing it as a speculative pump.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

CROs weak price performance and concerns about its expanding token supplyespecially the communitys belief that previously burned tokens were restored and could keep adding sell pressuredominate discussion. Some traders see the low price as an accumulation opportunity, while others remain skeptical about management and the tokens prospects; no clear bullish catalyst is broadly established.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is repeatedly named by traders as a possible acquirer of SELLAS, with speculation centered on its AML drug portfolio and SELLASs investigational therapies; no deal is confirmed, and the bullish buyout thesis is disputed. Separately, traders discuss ABBVs strong run and new highs amid a rotation into healthcare, while some question whether the rally can hold.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash is drawing attention over a roughly $131 million New York settlement tied to alleged underpayment of delivery workers, alongside required wage oversight. Traders are debating the potential cost to margins and whether the case could prompt similar actions elsewhere, while others view the settlement as manageable.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2026...

Atara Biotherapeutics Announces Changes to Its Board of Directors

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the departure of Carol Gallagher, Pharm D from...

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA PR Newswire NEW YORK, May 26, 2026...

ATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 2024 and January 9, 2026. Atara describes itself as a company that develops therapies for patients...

ATRA FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA) and reminds investors of the May 22, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that...

ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know

Atara stock soars 82% as the FDA outlines a regulatory pathway for its lead product candidate, tab-cel, reviving hopes for potential U.S. approval, after two prior CRLs.

ATRA EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026

ATRA EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 ATRA EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026...

Deadline Soon: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz reminds investors of the upcoming May 22, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA) securities between May...

Atara Biotherapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 22, 2026 to Discuss Your Rights - ATRA

Atara Biotherapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 22, 2026 to Discuss Your Rights - ATRA Atara Biotherapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 22, 2026 to Discuss Your...

ATRA UPCOMING DEADLINE : The Gross Law Firm Alerts Atara Biotherapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm

ATRA UPCOMING DEADLINE : The Gross Law Firm Alerts Atara Biotherapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm ATRA UPCOMING DEADLINE : The Gross Law Firm Alerts Atara...

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Atara Biotherapeutics Inc

ATRA Stock Sees Biggest Single-Day Gain In Over 2 Years, Breaches Key Technical Milestone – New FDA Update Has Bulls Circling Back

Equity

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

ATRA Atara Biotherapeutics Inc

Fundamentals

Latest ATRA News